Abstract
Today the quest for new diagnostic and therapeutic agents is a fervent search akin to the gold miners and prospectors of the gold rush in the mid-1800s. While rejected rocks far outnumbered genuine gold nuggets, the hope of discovery despite endless time searching kept these prospectors motivated. Discovering novel diagnostic or therapeutic agents is a similar process as vast resources and time are spent synthesizing and testing tens of thousands of potential candidate molecules from preclinical discovery through the US Food and Drug Administration (FDA) approval process. It is, however, a process that can be streamlined if trialists efficiently manage and leverage all available resources at strategic stages of the clinical trial.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Novel Designs of Early Phase Trials for Cancer Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
